# An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

> **NCT05223920** · PHASE2 · COMPLETED · sponsor: **Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)** · enrollment: 81 (actual)

## Conditions studied

- Thrombocythemia, Essential
- Primary Myelofibrosis

## Interventions

- **DRUG:** Bomedemstat

## Key facts

- **NCT ID:** NCT05223920
- **Lead sponsor:** Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-15
- **Primary completion:** 2024-08-22
- **Final completion:** 2024-08-22
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05223920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05223920, "An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05223920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*